Buprenorphine ER is under clinical development by Emplicure and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Buprenorphine ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Buprenorphine ER overview

Buprenorphine (EMPLI-03) is under development for the treatment of chronic pain. It is administered as an oral buccal extended-release tablet and is being developed based on Emplior platform.

Emplicure overview

Emplicure is a pharmaceutical company. It develops a new generation of products by combining existing and approved substances with proprietary biomaterial technologies. The company’s major products include EMPLI03, EMPLI04, EMPLI20, EMPLI21, EMPLI16, EMPLIADHD, AMP01, AMP10 drug candidates. Its drug candidates are used for the treatment of chronic pain, aims to reduce the risk for opioid abuse and addiction. The company’s administration platforms include emplior, empliderm, emplihale. It develops a product for fast deliver of potent drugs based on a microneedle technology using self-setting bioceramics, and the active substance is incorporated in the ceramic material which is molded into micro-needles developed to provide painless administration, like an intravenous injection, and others. Emplicure is headquartered in Uppsala, Sweden.

For a complete picture of Buprenorphine ER’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.